Neurocrine Biosciences has published a journal paper about its phase 3 trial of tardive dyskinesia candidate Ingrezza.

Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.

Arriving later to the PCSK9 inhibitor market could actually be beneficial to Alnylam and The Medicines Company, say analysts.

Eli Lilly was hit earlier this month when rival Novartis became the second, after front-runner Pfizer, to gain FDA approval for its CDK 4/6 inhibitor Kisqali (…

A phase 3 trial of Nektar Therapeutics’ chronic pain asset NKTR-181 has met its primary endpoint. The clinical trial linked the mu-opioid to a statistically…

Researchers who worked at GlaxoSmithKline before leading RespiVert to a takeover by Johnson & Johnson have raised $30.4 million (£24.5 million) for their…

Array BioPharma has yanked its NDA to the U.S. regulator for its late-stage melanoma candidate binimetinib after the agency told the biotech its phase 3 Nemo…

The FDA has rejected AstraZeneca’s hyperkalemia drug ZS-9 for the second time in 12 months. The news marks a further blow for a program AstraZeneca saw giving…

R&D